Scientists in the U.S. and abroad are examining the characteristics and usefulness of induced pluripotent stem cells, adult cells that are reprogrammed to become embryoniclike stem cells, after discovering slight differences that could affect the potential of iPS cells in treating diseases. "We are getting a variety of signals that suggest they are different [from embryonic stem cells] in key ways, and the road to using them as a therapy will require much more refinement of this big tool," said Konrad Hochedlinger, a chief faculty member at the Harvard Stem Cell Institute.

Related Summaries